Ryan J. Sullivan, MD

Cancer Network spoke with Ryan J. Sullivan, MD, of Massachusetts General Hospital, about the debate between immunotherapy sequencing vs targeted therapy for melanoma.

This review summarizes the current available treatment strategies for patients with advanced melanoma when PD-1–directed therapy is not enough.

Cancer Network spoke with Ryan J. Sullivan, MD, about the efficacy and safety of entinostat plus pembrolizumab in patients previously treated with immunotherapy.

Cancer Network speaks with Dr. Ryan J. Sullivan about adjuvant therapies in development for melanoma patients.

Medical oncologist Ryan J. Sullivan shared some interesting melanoma-related presentations from the  2018 ASCO Annual Meeting.

In early 2015, determining the optimal treatment regimen for a patient with metastatic melanoma remains challenging.